Open Orphan subsidiary wins 'important' new contract
Pharmaceutical contract research organisation Open Orphan secured an "important" new contract to support an unnamed European client via its French subsidiary, Venn Life Sciences.
Open Orphan said on Tuesday that the Venn team in Paris would assist the mystery customer with a prospective, multicentre, longitudinal, non-interventional oncology study.
The AIM-listed group expects to enrol over 750 subjects in the study, while Venn will handle all data management, statistics and medical writing for the project.
Chairman Cathal Friel said: "This industry-leading team in our Paris office has the knowledge and track record which has allowed us to continue to grow the business by winning large, long-term contracts such as the one we have announced today.
"We look forward to delivering on the contract and continuing to support large pharmaceutical companies as we rapidly grow Open Orphan."
As of 0940 BST, Open Orphan shares were down 2.21% at 14.52p.